



Technical Memorandum

TO: Physicians, Clinical Staff and Clients

From: Wesley J. Kim, M.D. Ana Ortega-Lopez, M.D. Amy Powers, MD
DLS Medical Director QMC Lab Director PSC Lab Director

Date: August 26, 2025

Subject: Lupus Anticoagulant Testing (dRVVT) and Introduction of Activated Protein C Resistance (APCR) Testing

Transition of Lupus Anticoagulant (dRVVT) – Effective August 26, 2025

DLS will transition Lupus Anticoagulant (dRVVT) testing from the Stago platform to the Werfen system. Key details include:

- Reference ranges remain unchanged
 - Example: Screen/Confirm ratio ≤ 1.20
- Interpretation protocol will continue using the established three-step algorithm:
 - Screening
 - Mixing
 - Confirmation
- Reporting format update:
 - Results will shift from clotting times (seconds) to ratio-based results

Introduction of Functional Activated Protein C Resistance (APCR) Assay

DLS will also introduce a functional APCR assay, a phenotypic clot-based test used as the first-line method to assess APC resistance.

Highlights:

- Detects both genetic (e.g., Factor V Leiden) and acquired APC resistance
- Shows high concordance with molecular genotyping
- Offers significant cost-efficiency
- Molecular Factor V Leiden testing may be reserved for confirmation only when indicated

Important Testing Considerations

Do not order Functional APCR or Lupus Anticoagulant (dRVVT) assays in patients currently receiving anticoagulant therapy, including:

- Direct oral anticoagulants (e.g., factor Xa and thrombin inhibitors)
- Unfractionated heparin
- Low molecular weight heparin

These agents can mask or mimic pathological findings, leading to:

- False positive or false negative results
- Compromised assay interpretation

If you have any questions, please call Client Services at 808-589-5101.

“Great Science – Great People”

Diagnostic Laboratory Services, Inc., 99-859 Iwaiwa St., Aiea, HI 96701